Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00989625 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.
A Phase 1 study of Migraine Disorders, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT00989625: Completed Phase 1 study of Migraine Disorders, sponsored by GlaxoSmithKline.
NCT00989625 is a Phase 1 study of Migraine Disorders that has completed, run by GlaxoSmithKline. The registered enrollment target is 50 participants, below the 313-participant average among 21 other Migraine Disorders trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00989625, a Phase 1 study of Migraine Disorders, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a pharmacokinetic (PK) study designed to investigate a combination product containing sumatriptan succinate and naproxen sodium administered at 3 single doses (10mg sumatriptan/60mg naproxen sodium, 30mg sumatriptan/180mg naproxen sodium, 85mg sumatriptan/500mg naproxen sodium) in adolescent migraine patients. The same doses will be also administered to a group of healthy volunteer (HV) adult subjects and the PK parameters will be compared between these two groups and between doses.
Conditions Studied
Interventions
- DRUG This is a pharmacokinetic study (Treximet)
Study Locations (3)
Kansas
- GSK Investigational Site - Wichita
Kentucky
- GSK Investigational Site - Louisville
Tennessee
- GSK Investigational Site - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-11-04 |
| Est. Completion | 2009-09-10 |
| Phase | Phase 1 |
What the finished NCT00989625 record still lists
NCT00989625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 313-participant average among 21 other Migraine Disorders trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 1 intervention - of which This is a pharmacokinetic study (Treximet) is the first listed.
NCT00989625 reports a single indexed study location in Kansas, Kentucky, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00989625 about?
NCT00989625 is a clinical study titled "A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.". This is a pharmacokinetic (PK) study designed to investigate a combination product containing sumatriptan succinate and naproxen sodium administered at 3 single doses (10mg sumatriptan/60mg naproxen sodium, 30mg sumatriptan/180mg naproxen sodium, 85mg sumatriptan/500mg naproxen sodium) in adolescent...
What is the current status of trial NCT00989625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2008-11-04. Estimated completion is 2009-09-10.
What conditions does trial NCT00989625 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT00989625?
The interventions under investigation include: This is a pharmacokinetic study (Treximet) (DRUG).
Who is sponsoring clinical trial NCT00989625?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00989625 being conducted?
This trial has 3 study locations across Kansas, Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00989625's enrollment target sits among peer trials
50 18th of 21 higher than 4 of 21 other Migraine Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)
COMPLETED · Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
RECRUITING · Phase 4
-
Mind Body Balance for Pediatric Migraine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI